BMC microbiology · 2025
Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bientz Léa, Boijout Hugo, Grami Raoudha, Guyet Ulysse, Lahouati Marin, Hertzmann Melissande, Marques Antony, Toirot Audrey, Aillerie Sabine, Coulange-Mayonnove Laure, Groppi Alexis, Nikolski Macha, Bébéar Cécile, Dubois Véronique
Аннотация
OBJECTIVES: Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms underlying resistance in P. aeruginosa isolates after ceftolozane/tazobactam treatment as well as alternative therapeutic options.
METHODS: Antimicrobial susceptibility was assessed with the disc diffusion method and minimum inhibitory concentration (MIC) determination. Resistance genes and sequence types (ST) were determined by whole genome sequencing (WGS). The ceftolozane/tazobactam resistance mechanism was explored by cloning ampC into the ampC-deficient strain PAO1 and blaAmpC expression experiments.
RESULTS: Of 50 patients treated, 9 (18%) acquired one or more ceftolozane/tazobactam-resistant isolates during treatment. WGS revealed various mutations in the ampC gene, namely, Thr70Ile, Phe121Leu, Pro154Leu, Gly157Asp, del210-216, Glu221Lys, and the new mutation, Pro217Gln. Cloning experiments revealed that the Pseudomonas-derived cephalosporinase (PDC) polymorphism did not alter mutation effects, mutations did not confer the same resistance level, and those conferring the strongest resistance restored susceptibility to piperacillin, piperacillin/tazobactam and imipenem despite changes in the oprD gene. In clinical isolates, the resistance level conferred by the same mutations differed, indicating the involvement of other mechanisms, particularly the overproduction of AmpC, which is always present due to mutations mainly in AmpD. Finally, imipenem/relebactam, colistin, amikacin and cefiderocol could be good alternatives for treating ceftolozane/tazobactam-resistant strains.
CONCLUTION: Ceftolozane/tazobactam resistance development was associated mainly with chromosomal mutations in the ampC gene but also with mutations in its regulatory genes. Knowledge about these mutations and gene polymorphisms is essential for interpreting resistance phenotypes from genomic data.
METHODS: Antimicrobial susceptibility was assessed with the disc diffusion method and minimum inhibitory concentration (MIC) determination. Resistance genes and sequence types (ST) were determined by whole genome sequencing (WGS). The ceftolozane/tazobactam resistance mechanism was explored by cloning ampC into the ampC-deficient strain PAO1 and blaAmpC expression experiments.
RESULTS: Of 50 patients treated, 9 (18%) acquired one or more ceftolozane/tazobactam-resistant isolates during treatment. WGS revealed various mutations in the ampC gene, namely, Thr70Ile, Phe121Leu, Pro154Leu, Gly157Asp, del210-216, Glu221Lys, and the new mutation, Pro217Gln. Cloning experiments revealed that the Pseudomonas-derived cephalosporinase (PDC) polymorphism did not alter mutation effects, mutations did not confer the same resistance level, and those conferring the strongest resistance restored susceptibility to piperacillin, piperacillin/tazobactam and imipenem despite changes in the oprD gene. In clinical isolates, the resistance level conferred by the same mutations differed, indicating the involvement of other mechanisms, particularly the overproduction of AmpC, which is always present due to mutations mainly in AmpD. Finally, imipenem/relebactam, colistin, amikacin and cefiderocol could be good alternatives for treating ceftolozane/tazobactam-resistant strains.
CONCLUTION: Ceftolozane/tazobactam resistance development was associated mainly with chromosomal mutations in the ampC gene but also with mutations in its regulatory genes. Knowledge about these mutations and gene polymorphisms is essential for interpreting resistance phenotypes from genomic data.